TargetBeta
GNRH1
gonadotropin releasing hormone 1 · also LNRH, GRH, GNRH, LHRH · Gonadotropin releasing hormone family
2 programs in company-led studies act on GNRH1, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Goserelinrule | AstraZeneca | phase 4 | 141 running | GNRHR | NCIt |
| triptorelinrule | Ipsen | phase 4 | 210 running | GNRHR | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Prostatic Neoplasms, 2 programs
- Breast Neoplasms, 1 program
- Metrorrhagia, 1 program
- Ovarian Hyperstimulation Syndrome, 1 program
- Puberty, Precocious, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 30, 2027Goserelin · AstraZeneca · phase 4 · NCT07310420
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.